204 related articles for article (PubMed ID: 29636367)
1. Disruption of
Bui N; Huang JK; Bojorquez-Gomez A; Licon K; Sanchez KS; Tang SN; Beckett AN; Wang T; Zhang W; Shen JP; Kreisberg JF; Ideker T
Mol Cancer Ther; 2018 Jul; 17(7):1585-1594. PubMed ID: 29636367
[TBL] [Abstract][Full Text] [Related]
2. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
3. NSD1 inactivation defines an immune cold, DNA hypomethylated subtype in squamous cell carcinoma.
Brennan K; Shin JH; Tay JK; Prunello M; Gentles AJ; Sunwoo JB; Gevaert O
Sci Rep; 2017 Dec; 7(1):17064. PubMed ID: 29213088
[TBL] [Abstract][Full Text] [Related]
4. Histone Methyltransferase G9a Drives Chemotherapy Resistance by Regulating the Glutamate-Cysteine Ligase Catalytic Subunit in Head and Neck Squamous Cell Carcinoma.
Liu CW; Hua KT; Li KC; Kao HF; Hong RL; Ko JY; Hsiao M; Kuo ML; Tan CT
Mol Cancer Ther; 2017 Jul; 16(7):1421-1434. PubMed ID: 28265008
[TBL] [Abstract][Full Text] [Related]
5. Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.
Papillon-Cavanagh S; Lu C; Gayden T; Mikael LG; Bechet D; Karamboulas C; Ailles L; Karamchandani J; Marchione DM; Garcia BA; Weinreb I; Goldstein D; Lewis PW; Dancu OM; Dhaliwal S; Stecho W; Howlett CJ; Mymryk JS; Barrett JW; Nichols AC; Allis CD; Majewski J; Jabado N
Nat Genet; 2017 Feb; 49(2):180-185. PubMed ID: 28067913
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
7. Livin enhances chemoresistance in head and neck squamous cell carcinoma.
Yoon TM; Kim SA; Lee DH; Lee JK; Park YL; Lee KH; Chung IJ; Joo YE; Lim SC
Oncol Rep; 2017 Jun; 37(6):3667-3673. PubMed ID: 28440463
[TBL] [Abstract][Full Text] [Related]
8. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus-Associated Head and Neck Cancer.
Biktasova A; Hajek M; Sewell A; Gary C; Bellinger G; Deshpande HA; Bhatia A; Burtness B; Judson B; Mehra S; Yarbrough WG; Issaeva N
Clin Cancer Res; 2017 Dec; 23(23):7276-7287. PubMed ID: 28916527
[No Abstract] [Full Text] [Related]
9. NSD1 mutations by HPV status in head and neck cancer: differences in survival and response to DNA-damaging agents.
Pan C; Izreig S; Yarbrough WG; Issaeva N
Cancers Head Neck; 2019; 4():3. PubMed ID: 31321084
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression signature regulated by the KEAP1-NRF2-CUL3 axis is associated with a poor prognosis in head and neck squamous cell cancer.
Namani A; Matiur Rahaman M; Chen M; Tang X
BMC Cancer; 2018 Jan; 18(1):46. PubMed ID: 29306329
[TBL] [Abstract][Full Text] [Related]
11. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
12. KiSS1 mediates platinum sensitivity and metastasis suppression in head and neck squamous cell carcinoma.
Jiffar T; Yilmaz T; Lee J; Hanna E; El-Naggar A; Yu D; Myers JN; Kupferman ME
Oncogene; 2011 Jul; 30(28):3163-73. PubMed ID: 21383688
[TBL] [Abstract][Full Text] [Related]
13. Decitabine rescues cisplatin resistance in head and neck squamous cell carcinoma.
Viet CT; Dang D; Achdjian S; Ye Y; Katz SG; Schmidt BL
PLoS One; 2014; 9(11):e112880. PubMed ID: 25391133
[TBL] [Abstract][Full Text] [Related]
14. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
15. The FA/BRCA Pathway Identified as the Major Predictor of Cisplatin Response in Head and Neck Cancer by Functional Genomics.
Martens-de Kemp SR; Brink A; van der Meulen IH; de Menezes RX; Te Beest DE; Leemans CR; van Beusechem VW; Braakhuis BJ; Brakenhoff RH
Mol Cancer Ther; 2017 Mar; 16(3):540-550. PubMed ID: 27980104
[TBL] [Abstract][Full Text] [Related]
16. Chromatin dysregulation associated with NSD1 mutation in head and neck squamous cell carcinoma.
Farhangdoost N; Horth C; Hu B; Bareke E; Chen X; Li Y; Coradin M; Garcia BA; Lu C; Majewski J
Cell Rep; 2021 Feb; 34(8):108769. PubMed ID: 33626351
[TBL] [Abstract][Full Text] [Related]
17. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
18. Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis.
Gameiro SF; Ghasemi F; Zeng PYF; Mundi N; Howlett CJ; Plantinga P; Barrett JW; Nichols AC; Mymryk JS
Infect Agent Cancer; 2021 Feb; 16(1):13. PubMed ID: 33588906
[TBL] [Abstract][Full Text] [Related]
19. Cancer stem cell mediated acquired chemoresistance in head and neck cancer can be abrogated by aldehyde dehydrogenase 1 A1 inhibition.
Kulsum S; Sudheendra HV; Pandian R; Ravindra DR; Siddappa G; R N; Chevour P; Ramachandran B; Sagar M; Jayaprakash A; Mehta A; Kekatpure V; Hedne N; Kuriakose MA; Suresh A
Mol Carcinog; 2017 Feb; 56(2):694-711. PubMed ID: 27380877
[TBL] [Abstract][Full Text] [Related]
20. DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.
Martens-de Kemp SR; Dalm SU; Wijnolts FM; Brink A; Honeywell RJ; Peters GJ; Braakhuis BJ; Brakenhoff RH
PLoS One; 2013; 8(4):e61555. PubMed ID: 23613873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]